CLINICAL TRIALS PROFILE FOR SOMATULINE DEPOT
✉ Email this page to a colleague
All Clinical Trials for SOMATULINE DEPOT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00149188 ↗ | Somatuline Autogel: Acromegaly Self/Partner Injection Study | Completed | Ipsen | Phase 4 | 2004-02-01 | The purpose of this study is to allow patients with acromegaly, or their partners, to learn how to successfully inject Somatuline Autogel at home. Ability to perform unsupervised injections whilst maintaining adequate disease control will be assessed. |
| NCT00216398 ↗ | Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR | Completed | Ipsen | Phase 4 | 2004-06-01 | The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR. |
| NCT00288522 ↗ | Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment | Terminated | Ipsen | Phase 2 | 2006-01-01 | The main purpose of this study is to evaluate the efficacy and safety of 3 doses of Somatuline Autogel 60mg to control the muscle infiltration and edema, eyelid retraction and extraocular muscular contraction in patients with active thyroid-associated ophthalmopathy of moderate intensity. |
| NCT00444873 ↗ | Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly | Completed | Ipsen | Phase 3 | 2005-01-01 | A multicentre, prospective, open label study of acromegalic patients evaluating the efficacy and safety of different dose-intervals of Lanreotide Autogel 120mg according to international standards and compared to previous treatment with Octreotide LAR 10, 20 or 30 mg. |
| NCT00447499 ↗ | Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel | Completed | Ipsen | Phase 3 | 2007-04-01 | The purpose of this study is to determine whether subjects with acromegaly (or their partners) are able to self administer Somatuline Autogel at home. |
| NCT00517491 ↗ | Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) | Withdrawn | Ipsen | Phase 2 | 2008-05-01 | The purpose of the protocol is to evaluate the correlation between plasma lanreotide levels and Growth Hormone (GH)/Insulin Like Growth Factor 1 (IGF-1) dynamics and clinical improvement in patients with acromegaly treated with lanreotide Autogel (Somatuline ATG) |
| NCT00681187 ↗ | Somatuline Autogel Preference and Health Economy Study | Completed | Ipsen | Phase 4 | 2008-06-01 | The primary aim of this study is to assess which method of lanreotide Autogel administration patients with neuroendocrine tumours prefer - self/partner administrations or healthcare provided administrations. The study will also assess if self/partner administration can be performed without loss of efficacy and with a preserved safety profile. The impact of self/partner administration on resource utilisation and costs will be studied. In addition, we will also assess the healthcare provider's experience of the two administration practices. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SOMATULINE DEPOT
Condition Name
Clinical Trial Locations for SOMATULINE DEPOT
Trials by Country
Clinical Trial Progress for SOMATULINE DEPOT
Clinical Trial Phase
Clinical Trial Sponsors for SOMATULINE DEPOT
Sponsor Name
